Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:FBLG

FibroBiologics Q1 2025 Earnings Report

FibroBiologics logo
$1.24 +0.04 (+2.90%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.17 -0.07 (-5.32%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

FibroBiologics EPS Results

Actual EPS
-$2.40
Consensus EPS
-$2.20
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q1 2025
Date
7/31/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

FibroBiologics' Q3 2026 earnings is estimated for Friday, October 30, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q3 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

FibroBiologics' Q1 2025 Quarterly reportQuarterly report
(10-Q)

FibroBiologics Earnings Headlines

FibroBiologics Secures European Patent For Fibroblast Therapeutic Technology; Stock Up
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695207/fibrobiologics-secures-european-patent-for-fibroblast-therapeutic-technology-stock-up.aspx
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
September 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/fibrobiologics-announces-grant-of-european-patent-for-methods-of-enhancing-fibroblast-therapeutic-activity-302892133.html
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 4 at 1:00 AM  |  Stansberry Research (Ad)
RedChip Companies, Inc.: Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV
September 25, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69679044-redchip-companies-inc-nova-minerals-and-fibrobiologics-interviews-to-air-nationally-on-the-redchip-small-stocks-big-money-show-on-cnbc-and-bloombe-200.htm
FibroBiologics Inc. (NASDAQ:FBLG) Receives Consensus Rating of "Reduce" from Analysts
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041722
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
September 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4948804-fibrobiologics-inc-fblg-discusses-strategy-and-clinical-progress-in-fibroblast-based-cell
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. The company’s research focuses on fibroblasts, a type of cell involved in tissue maintenance and repair, and the biologically active factors and extracellular vesicles that these cells produce.

FibroBiologics is developing a proprietary platform intended to generate therapeutic products from fibroblast-derived cells and their secretions. Its pipeline is aimed at conditions associated with tissue damage, inflammation, and impaired regeneration, including multiple sclerosis, psoriasis, and degenerative disc disease. The company’s programs remain in clinical and preclinical development, and its product candidates are not broadly approved for commercial use.

FibroBiologics is headquartered in Houston, Texas, and is led by founder and Chief Executive Officer Pete O’Heeron. The company became a publicly traded business on Nasdaq under the symbol FBLG in 2024.

View FibroBiologics Profile
Earnings Tools